Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2015 May;13(5):515-24.
doi: 10.6004/jnccn.2015.0071.

Non-Small Cell Lung Cancer, Version 6.2015

David S Ettinger  1 , Douglas E Wood  1 , Wallace Akerley  1 , Lyudmila A Bazhenova  1 , Hossein Borghaei  1 , David Ross Camidge  1 , Richard T Cheney  1 , Lucian R Chirieac  1 , Thomas A D'Amico  1 , Todd L Demmy  1 , Thomas J Dilling  1 , M Chris Dobelbower  1 , Ramaswamy Govindan  1 , Frederic W Grannis Jr  1 , Leora Horn  1 , Thierry M Jahan  1 , Ritsuko Komaki  1 , Lee M Krug  1 , Rudy P Lackner  1 , Michael Lanuti  1 , Rogerio Lilenbaum  1 , Jules Lin  1 , Billy W Loo Jr  1 , Renato Martins  1 , Gregory A Otterson  1 , Jyoti D Patel  1 , Katherine M Pisters  1 , Karen Reckamp  1 , Gregory J Riely  1 , Eric Rohren  1 , Steven E Schild  1 , Theresa A Shapiro  1 , Scott J Swanson  1 , Kurt Tauer  1 , Stephen C Yang  1 , Kristina Gregory  1 , Miranda Hughes  1 ; National comprehensive cancer network
Affiliations
Practice Guideline

Non-Small Cell Lung Cancer, Version 6.2015

David S Ettinger et al. J Natl Compr Canc Netw. 2015 May.

Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

PubMed Disclaimer

Publication types

MeSH terms